Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.50 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4616525 | 0.99 | HTR6 (0.49) | HTR6HTR1AHTR2AHTR7DRD2 | |
| SCHEMBL4613855 | 0.88 | HTR6 (0.64) | HTR6HTR1AHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL4614225 | 0.86 | HTR6 (0.63) | HTR6HTR1AHTR2AHTR7DRD2 | |
| SCHEMBL3857841 | 0.83 | HTR6 (0.50) | HTR6HTR1AHTR2AHTR7DRD2 | |
| SCHEMBL1136442 | 0.82 | HTR6 (0.48) | HTR6HTR1AHTR2AHTR7DRD2 | |
| SCHEMBL4615574 | 0.81 | HTR1A (0.47) | HTR6HTR1AHTR2ADRD2SLC6A2 | |
| Hydrochloric Acid SCHEMBL4615687 | 0.81 | HTR6 (0.48) | HTR6HTR1AHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL4632915 | 0.80 | HTR1A (0.46) | HTR6HTR1AHTR2ADRD2SLC6A2 | |
| SCHEMBL4673532 | 0.80 | HTR6 (0.78) | HTR6HTR1AHTR2AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL4677722 | 0.80 | HTR6 (0.76) | HTR6HTR1AHTR2AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | claimed |
| EP-1708713-B1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | claimed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | HTR6 894/4885HTR1A 731/4885HTR2A 977/4885 |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885HTR1A 5/4885HTR2A 2/4885 |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | HTR6 894/4885HTR1A 731/4885HTR2A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.